Camphor toxicity: Difference between revisions
(clinical features) |
ClaireLewis (talk | contribs) No edit summary |
||
| (8 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Common topical agent for pain relief, wart removal, osteoarthritis, cold sores | *Common topical agent for pain relief, wart removal, osteoarthritis, cold sores, cough suppression, nasal decongestion | ||
*FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref> | *FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref> | ||
*Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes | *Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes | ||
*CNS stimulant when ingested | |||
==Clinical Features== | ==Clinical Features== | ||
*Nausea | *[[Nausea/vomiting]], [[abdominal pain]] | ||
*Oral burning | *Oral burning | ||
*Vertigo, confusion, agitation | *[[Headache]] | ||
*Seizure, respiratory depression, coma | *[[Vertigo]], [[confusion]], [[agitation]] | ||
*Hepatitis and liver failure | *[[Seizure]], respiratory depression, [[coma]] | ||
*[[Hepatitis]] and [[liver failure]] | |||
==Differential Diagnosis== | |||
==Evaluation== | |||
==Management== | |||
*Aggressive supportive care<ref>American Academy of Pediatrics Policy Statement. Camphor Revisited: Focus on Toxicity (RE9422). Pediatrics 1994;94:127-128</ref> | |||
*[[Benzodiazepines]] for seizure | |||
*[[Intubation]] and [[mechanical ventilation]] as needed | |||
*[[Charcoal]] not likely effective | |||
==Disposition== | |||
==See Also== | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Toxicology]] | ||
Latest revision as of 02:14, 27 January 2019
Background
- Common topical agent for pain relief, wart removal, osteoarthritis, cold sores, cough suppression, nasal decongestion
- FDA limits over the counter preparations to 11%[1]
- Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes
- CNS stimulant when ingested
Clinical Features
- Nausea/vomiting, abdominal pain
- Oral burning
- Headache
- Vertigo, confusion, agitation
- Seizure, respiratory depression, coma
- Hepatitis and liver failure
Differential Diagnosis
Evaluation
Management
- Aggressive supportive care[2]
- Benzodiazepines for seizure
- Intubation and mechanical ventilation as needed
- Charcoal not likely effective